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Abstract Nanoparticles, although considered a topic of modern medicine, actually have an interesting 
history. Currently, advances in nanomedicine hold great promise as drug carrier systems for 
sustained release and targeted delivery of diverse therapeutic agents. Nanoparticles can be defined 
as complex drug carrier systems which incorporate and protect a certain drug or particle. 
Nanoparticles can be administered via different routes, such as intravenous injection, oral 
administration, or pulmonary inhalation. Even though the use of nano-carriers via pulmonary 
inhalation is heavily debated, this system represents an attractive alternative to the intravenous or 
oral routes, due to the unique anatomical and physiological features of the lungs and the minimal 
interactions between the targeted site and other organs. Some of the widely used nano-carriers for 
the treatment of chronic pulmonary diseases, via pulmonary route, are as follows: polymeric 
nanoparticles, liposomal nano-carriers, solid lipid nanoparticles, and submicron emulsions. Nano-
carrier systems provide the advantage of sustained-drug release in the lung tissue resulting in 
reduced dosing frequency and improved patient compliance. Further studies focusing on 
understanding the mechanisms of action of nanoparticles and improving their chemical structure 
are required in order to better understand the potential long-term risk of excipient toxicity and 
nanoscale carriers. 
Keywords  nanoparticles, chronic lung diseases, therapy, sustained drug release, patient compliance 
Highlights ✓ In chronic lung diseases, nano-carrier systems provide the advantage of sustained drug 
release in lung tissue, resulting in reduced dosing frequency and improved patient 
compliance. 
✓ Further studies are required in order to better understand the potential long-term risk of 
excipient toxicity and nanoscale carriers. 
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Introduction 
Nanoparticles, although considered a topic of modern 
medicine, actually have an interesting history, as their use 
dates back to the 9th century Mesopotamia, where they 
were used by manufacturers to create a glittering effect on 
the surface of pots. They were created by mixing copper, 
silver salts, and oxides, together with vinegar, ochre, and 
clay, on the surface of previously-glazed pottery. The 
object was then placed in an oven and heated to about 
600°C. 
The first scientific characterization—no longer in 
use—in terms of optical properties of nanometric metals 
was formulated by Michael Faraday in his classic paper 
“Experimental relations of gold (and other metals) to 
light”. The paper, both philosophical and scientific, 
described a series of experiments of ultramicroscopic 
particles of gold in various liquids, in order to establish 
whether their optical properties suffer any changes under 
such conditions. Faraday formulates the following 
statement: “It is well known that when thin leaves of gold 
or silver are mounted upon glass and heated to a 
temperature that is well below a red heat (~500 °C), a 
remarkable change of properties takes place, whereby the 
continuity of the metallic film is destroyed. The result is 
that white light is now freely transmitted, reflection is 
correspondingly diminished, while the electrical resistivity 
is enormously increased (1).  
In the late 1960s, Prof. Speiser at the Swiss Federal 
Institute of Technology in Zurich developed the first 
nanoparticles for drug delivery purposes and for vaccines 
against tetanus, diphtheria, and other infections (2). 
Currently, further advances in nanomedicine hold a great 
promise as drug carrier systems for sustained release and 
targeted delivery of diverse therapeutic agents (3). 
Nanoparticles can be defined as complex drug carrier 
systems, which incorporate and protect a certain drug or 
particle (4). Nanoparticles can be administered via 
different routes, such as intravenous injection, oral 
administration, and pulmonary inhalation. Due to their 
submicron sizes, intravenously injected nanoparticles can 
easily escape the altered blood vessels, such as those found 
in tumors, trauma, or inflammatory sites. In these 
pathological lesions, as a result of the defective lymphatic 
drainage of these tissues, nanoparticles are retained for 
longer periods of time (5). Using nanoparticles as oral drug 
carriers can protect the active ingredient in the 
gastrointestinal tract against proteolytic enzymes, prolong 
the action of the drug in the mucous membrane, and 
facilitate the drug transport across the intestinal mucosa, 
making this a comfortable drug administration method (4).  
Even though the use of nano-carriers via pulmonary 
inhalation is heavily debated, this system represents an 
attractive alternative to the intravenous or oral routes, due 
to the unique anatomical and physiological features of the 
lungs and the minimal interactions between the targeted 
site and other organs (6). 
Discussions 
The purpose of this research was to summarize the 
current literature regarding the advantages and 
disadvantages of the use of nanoparticles in the treatment 
of respiratory diseases, such as COPD (Chronic 
Obstructive Pulmonary Disease), asthma, lung cancer, or 
tuberculosis, the most clinical common chronic lung 
diseases. An important aspect to discuss is the last decade’s 
progress in the development of nano-carrier systems for the 
treatment of chronic pulmonary diseases, in terms of 
chemistry, bio-distribution, and toxicity. Over 2,500 
papers have been published in the past 10 years regarding 
nanoparticles, proving the exhaustive efforts that are 
focused on developing this new and promising class of 
drugs. 
An electronic search in PubMed database and Web of 
Science was conducted on publications from February 
2009 to February 2019. Only studies published in English 
were included. In the databases, the search used the 
following keywords “nanoparticles” and “respiratory 
disease”. The studies were then searched manually from 
the reference list through the databases. 
The inclusion criteria were: articles written in English, 
full-text articles, studies published in the last 10 years, and 
all studies performed in vitro, ex vivo, and in vivo. 
Exclusion criteria were literature reviews and studies about 
nanoparticles that were correlated with diseases other than 
chronic respiratory ones. The outcome measure in this 
research was the roles of nanoparticle therapy in chronic 
pulmonary diseases. 
The major advantages of nanoparticle-mediated drug 
delivery to the lung are attributed to the unique 
pharmacokinetic and pharmacodynamic properties of the 
system and the anatomical and physiological particularities 
of the respiratory tract. The human respiratory tract has a 
large surface area (greater than 100m2), a thin lung-blood 
barrier (approx. 0.1 microns), and a high perfusion rate, 
thus providing quick and efficient access to the circulatory 
system. Nanoparticles are particulate drug carrier systems 
which incorporate a certain drug in order to coat, protect, 
and increase its function. Drugs used for the treatment of 
pulmonary diseases can be administered via oral, 
intravenous, or inhalation routes, the last being the most 
Nanoparticles in the treatment of chronic lung diseases 
 226 
attractive option in terms of low side effects and high bio-
distribution (7).  
Drug delivery to the lung requires particles sized 
between 1 and 5 microns administered by means of 
nebulization, pressurized metered dose inhalers (MDI), 
and dry powder inhalers (DPI) (8). Metered dose inhalers 
are breath-actuated auto-halers that release the medication 
during inhalation, and there are no-breath-actuated 
pressurized inhalers in which medication is released by 
pushing the canister down into the holder, such as 
budesonide/formoterol or fluticasone propionate or 
salmeterol xinafoate (9). The active ingredients in MDI 
inhalers are dissolved or suspended in a propellant, and 
they are delivered via a compact pressurized aerosol 
dispenser. 
Dry powder inhalers are a group of inhalers that contain 
medication in very fine dry powder form. They are 
classified into single dose devices, multiple unit dose 
devices, and multi-dose devices. These tend to be more 
popular with patients because they are all breath-actuated. 
Examples of DPI are formoterol fumarate, mometasone 
furoate, salmeterol xinafoate, tiotropium bromide, and so 
on (10). The rate required to deliver the medication in MDI 
inhalers is about 30L/min, while the rate required for DPIs 
is higher (ranging between 30-120L/min) (10). 
In the case of DPI, the force of inhalation plays a key 
role in the deposition of particles. If the force is 
insufficient, the particles will not reach the lungs and will 
be deposited in the upper airways (mouth, pharynx, larynx 
and trachea). For MDI, despite the high speed of the 
generated aerosol, the key role is represented by good 
synchronization between the inhalation and the 
administration of the drug (9). 
For a better penetration through the respiratory mucosa 
and an enhanced local effect, the idea of administering 
classic therapies, such as bronchodilators, anti-
inflammatories, chemotherapy, or tuberculostatic agents 
through nano-particulate formulations has emerged. 
The pharmacodynamics of nanoparticle carrier systems 
is as follows: once the nano-carrier formulation reaches the 
lung, it goes through mucociliary clearance (MCC) and 
clearance. The mucociliary clearance transports the 
particles and the mucus produced by the lung epithelium 
towards the upper airways to be swallowed. Meanwhile, 
some of the particulate material is recognized by the 
antigen presenting cells, such as alveolar macrophages and 
dendritic cells.  The alveolar macrophages depredate and 
possibly deposit the drug, therefore the material ending up 
here is mostly lost (11). Dendritic cells present the drug to 
the nearby lymph nodes where they are recognized by the 
lymphocytes, leading to an immune reaction, thus 
providing a new alternative for the administration of 
antigens and vaccines. Only a small part of the inhaled 
nano-particulate formulations is able to avoid the 
mucociliary clearance, therefore various muco-penetrative 
molecules are being researched. Two major ideas have 
emerged: some studies show that small particles with a 
hydrophilic surface layer and a slight negative charge have 
a higher chance of penetrating the mucus (12). Other 
studies show that the addition of polyethene-glycolic acid 
to the surface of the nanoparticle (known as the process of 
PEGylation) provides an increased diffusion in human 
mucus and prevents the formation of drug aggregates (13).  
The major benefits of nanoparticles administered to the 
lung are as follows: uniform distribution of the drug (14, 
15), enhanced solubility and dissolution rate (16, 17), 
sustained release (18), delivery of various macromolecules 
(19, 20), and internalization by cells (21, 22).  
Some of the widely used nano-carriers for the treatment 
of chronic pulmonary diseases, via the pulmonary route, 
are as follows: polymeric nanoparticles, liposomal nano-
carriers, solid lipid nanoparticles, and submicron 
emulsions (23). 
➢ Polymeric nanoparticles are composed of 
biodegradable or biocompatible materials such as 
polylactic acid, alginic acid, gelatin, and chitosan, which 
results in prolonged drug release (24). They are currently 
used in several chronic pulmonary diseases such as asthma, 
tuberculosis (TB) (25, 26), and pulmonary hypertension 
(27). 
➢ Liposomal nano-carriers are uni-multi-lamellar 
spherical nanoparticles made of lipid bilayer membranes, 
including cholesterol and phosphatidylcholine, delivered 
in a liquid and dry powder form (28-31). The most valuable 
function of this nano-system is the increase in cellular 
uptake of the drug due to the presence of cells penetrating 
peptides. They have proven themselves useful in treating 
respiratory distress syndrome (32). 
➢ Solid lipid nano-carriers are composed of solid lipids, 
surfactants, and water. They have less or almost no 
cytotoxic effect compared to the polymer-based carriers, as 
shown in different studies: in vitro, ex vivo, and in vivo 
(33-35). Their main use is represented by lung cancer 
treatment and TB (tuberculosis) vaccine delivery. Solid 
lipid nano-carriers represent a multifunctional strategy in 
which a single molecule allows detection, diagnosis, 
imaging, cell destruction, and delivery of drugs, decreasing 
drug-related side effects (36, 37). More tolerable to the 
lungs and major advantages of solid lipid nanoparticles are 
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the controlled release of drugs with rapid in vivo 
degradation (38-40). 
➢ Submicron emulsions are promising carriers for DNA 
vaccines (e.g. Mycobacterium tuberculosis) to the lung 
compared to the commercially available liposomes. The 
emulsion systems are able to transfect pulmonary epithelial 
cells, which directly activate dendritic cells, resulting in the 
stimulation of antigen-specific T-cells (41). 
The type of formulation, composition, shape, and size 
are all important determinants in the pulmonary delivery of 
nanoparticles (42, 43).  
The delivery of the drug requires drug formulations 
capable of inhalation and delivery of the active component 
to the lower respiratory tract (44). In vivo, the particle size-
dependent regional deposition in the lung is variable, 
explaining why all particles or droplets must range between 
1 μm and 5 μm in diameter (45, 46). In general, particles 
larger than 5–6 μm are exhaled, while ultrafine particles 
(1–2 μm) are usually deposited in the bronchioles.  
Nanoscale particles (<1 μm) can be delivered to the alveoli. 
Particles smaller than 20 nm, such as dendrimers are also 
delivered to the alveoli, but they rapidly enter the 
bloodstream and so become retained in the lungs (47).  
In vitro, the endocytosis of nanoparticles is also 
strongly dependent on their charge (48). As already 
explained, PEGylation is a well-known process which 
consists in attaching  strands of polyethylene glycol to the 
surface of certain molecules, thus changing the 
conformation, electrostatic binding, hydrophobicity, and 
immunogenicity of the molecule, resulting in enhanced 
epithelial penetration, slower uptake, aggregation in and 
degradation of nano-particulate formulations by the 
reticuloendothelial system, longer steady-state 
concentrations,  less frequent administrations, and lower 
dosages. The first PEGylated drug approved by FDA in 
1990 was ADAGEN, used to treat a form of severe 
combined immunogenicity syndrome. PEGylation has 
become a common characteristic of various medications 
ever since (49).  
PEGylation of nano-carriers could be beneficial, by 
helping to overcome physiological barriers in the alveolar 
epithelium, thus resulting in enhanced penetration across 
the mucosal barrier and promoting entry into alveolar 
epithelial cells (50). Another major impediment has been 
overcome through the use of PEGylation, that is, the quick 
uptake, aggregation in, and degradation of nano-particulate 
formulations by the reticuloendothelial system. Through 
PEGylating nano-carriers, the frequency of administration 
and also the dosage can be reduced. Some studies have 
proven a lower tendency to the aggregation of the 
PEGylated nano-molecules, versus the non-PEGylated 
ones. Aggregation can lead to the nanoparticle entrapment 
in the liver, lungs, or elsewhere due to capillary occlusion 
(51). So, various types of nanoparticles have been 
developed over the last decades. These particles are able to 
enhance the pharmacokinetics of multiple drugs, 
potentially providing accurate and controlled drug delivery 
(52). 
 The phrase “respiratory diseases” comprises multiple 
disorders affecting the pulmonary system, the more 
frequent ones being COPD, asthma, lung cancer, and 
tuberculosis (53). The respiratory tract has several unique 
advantageous anatomical and physiological features. The 
large surface area, combined with an extremely thin lung-
blood barrier, provides direct access to the central 
circulation while creating conditions that are well suited for 
the efficient mass transfer, as shown by in vitro, ex vivo 
and in vivo studies (54, 55). 
Asthma is characterized by the chronic inflammatory 
disorder of the airways associated with airway hyper-
responsiveness, which leads to airway inflammation and in 
time, to airway remodeling, with negative consequences on 
the quality of life. The current treatment strategies include 
inhaled corticosteroids, beta-agonist agents, and anti-
leukotrienes. These treatments reduce the symptoms, but 
do not prevent airway remodeling; moreover, long-term 
use of corticosteroids may result in immunosuppression 
and a predisposition to opportunistic infections.  Various 
particles have been evaluated for the treatment of asthma 
that is refractory to classical therapies: liposomes, solid-
lipid NP, telodendrimers, polyethyleneimine, chitosan, 
dendrimers, polylactic-co-glycolic acid, and CK30PEG 
(polyethene glycol linked to a 30-mer of poly-L-lysine via 
a single cysteine residue). CK30PEG is the latest new 
molecule studied for nanoparticle’s gene delivery 
therapeutic systems—not yet in use as it is still in phase I 
clinical trials.  
A recently completed clinical trial of inhaled gene 
therapy has raised many questions about this type of 
therapy (56). Validated studies indicate that steroids 
compacted with nanoparticles are able to achieve 
prolonged and higher benefits at the site of airway 
inflammation, compared to free inhaled steroids. This is 
probably a result of the prolonged and higher concentration 
of drug in the targeted area, resulting in a sustained 
bronchodilator effect (57). More recently, nano-particulate 
formulations of interleukin antibodies have proven useful 
in reducing asthma exacerbations in patients with allergic 
asthma.  Mepolizumab is an interleukin 5 antibody first 
approved by the FDA in 2015 and showing promising 
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results in reducing bronchial inflammation (58). Research 
studies are now trying to incorporate this molecule into 
nano-particulate formulations in order to enhance its 
efficiency. 
Chronic Obstructive Pulmonary Disease (COPD) 
comprises emphysema and chronic bronchitis, which result 
in a vast clinical presentation. Symptoms include difficulty 
breathing, cough, sputum production, and wheezing. 
Traditional treatments include anticholinergics, beta 
agonists, and inhaled corticosteroids, which can control the 
symptoms but do not cure the underlying disease. Many 
designs have been reported so far in the attempt to find a 
nano-therapeutic system that would be able to overcome 
the challenges of drug delivery in COPD. The most recent 
and promising model consists of an inhalable dry powder 
containing dimethyl fumarate, designed by using advanced 
particle engineering. The majority of the drug particles can 
reach the lower airways through this new system, thus 
providing an anti-inflammatory response in these 
otherwise hard to reach areas, resulting in fewer 
exacerbations, reduced symptoms such as dyspnea and 
coughing. This treatment shows great promise, especially 
in increasing the quality of life in COPD patients (52). 
Lung cancer is one of the most common cancers in the 
world, being the leading cause of cancer death worldwide. 
Standard therapies currently include chemotherapy and/or 
surgery. While chemotherapeutic agents effectively kill 
cancer cells, their use and hence effectiveness are limited 
by toxicity. The aim of the current research is to create a 
multifunctional strategy delivered by a single molecule 
which allows the detection, diagnosis, imaging, cell 
destruction, and delivery of the drugs, decreasing drug-
related side effects. Polymeric micelle systems encoded 
with a lung-cancer targeting peptide and encapsulated with 
super magnetic iron oxide and Doxorubicin show great 
promise in the field of target-specific treatment of lung 
cancer. Nano-particulate formulations of classic 
chemotherapeutic agents have proven useful in reducing 
the chemotherapeutic side effects and increasing the 5-year 
survival rate (53). 
Tuberculosis is the leading cause of preventable deaths 
worldwide. Nanoparticle-based drug delivery systems may 
be considered for the treatment of tuberculosis due to the 
slow and sustained release of drugs such as classic 
tuberculostatic agents from the solid lipid nanoparticles 
both in vitro and in vivo, thus meaning the patients will 
undergo treatment fewer times per week, therefore 
increasing adherence to treatment and also the quality of 
life (50, 59, 60). 
One of the most debated topics regarding nano-
particulate formulations in the treatment of chronic 
pulmonary diseases are the potential side effects of this 
therapy. It is well-known that accidentally inhaled 
nanoparticles such as Diesel smoke or air pollutants are 
involved in the development of cardiovascular and 
respiratory diseases, like pulmonary fibrosis and other 
interstitial diseases. However, therapeutic nanoparticles 
show different clearance patterns than the toxic ones. It has 
been shown that non-biodegradable polymers provoke 
more toxicity and inflammation than biodegradable 
nanoparticles (54). A recent study reported that 
hydrophobic materials were the only ones that induced an 
inflammatory reaction, leading to asthma-like symptoms, 
while hydrophilic materials did not induce acute 
respiratory toxicity, which is why they are preferred as 
often as possible (55). 
Conclusions 
This review summarizes the potential beneficial effects 
of nanoparticle therapy in chronic lung diseases. Nano-
carrier systems provide the advantage of sustained drug 
release in lung tissue, resulting in reduced dosing 
frequency and improved patient compliance. Further 
studies focusing on understanding the mechanisms of 
action of nanoparticles and improving their chemical 
structure are required in order to better understand the 
potential long-term risk of excipient toxicity and nanoscale 
carriers. 
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